Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: David Cunningham
Woman and Man Max 99 years
David Cunningham
Update Il y a 5 ans
Molecular Markers of Prognosis in Colorectal Cancer Patients
To correlate the molecular profile of a series of defined CRCs with prognosis and toxicity.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham
Update Il y a 5 ans
Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours
The objective of this study is to assess the efficacy and toxicity of a 3 weekly regimen containing irinotecan combined with capecitabine in the setting of relapsed or refractory upper gas...
Country
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham, MD FRCP
Update Il y a 5 ans
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
This is a randomised, open-label phase II study comparing GEM-P chemotherapy (experimental arm) with CHOP (control arm) in previously untreated T-cell lymphoma. Eligible patients will be r...
Country
None
organs
None
Specialty
None
Opened trial
More information
Woman and Man Max 99 years
Professor David Cunningham, MD, FRCP
Update Il y a 5 ans
MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer)
The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy. Subjects invited to take part have met...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham, FRCP
Update Il y a 5 ans
A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
There has been considerable international /national interest in the GEM−P regimen for treatment of patients with relapsed/refractory lymphoma. Currently, there is no accepted standard ther...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham
Update Il y a 5 ans
Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer
To assess the efficacy and safety of gemcitabine given by fixed dose rate intravenous infusion in patients with pretreated metastatic colorectal cancer.
Country
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham
Update Il y a 5 ans
Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer
To assess the efficacy and safety of the combination of capecitabine and oxaliplatin in the 1st, 2nd or subsequent line treatment of metastatic colorectal cancer, and also in the neo-adjuv...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Cunningham
Update Il y a 5 ans
Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer
Knowledge of the impact of gene expression profiling could allow optimisation of chemotherapy regimens for individual patients. It could ensure that patients do not receive a particular fo...
Country
None
organs
None
Specialty
None
Opened trial
More information
Woman and Man Max 99 years
David Cunningham, MD FRCP
Update Il y a 5 ans
Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
To assess the activity of the FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2 amplified breast, squamous lung and stomach cancer whose cancers have progressed following previous che...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
David Cunningham, FRCP
Update Il y a 5 ans
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL)
Patients with aggressive Non−Hodgkin−lymphoma treated at first diagnosis with chemotherapy alone or combined chemo-radiotherapy can achieve high response rates. However, patients with rela...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
Next